Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Wrapmanager Inc.

Wrapmanager Inc. lowered its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 18.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,280 shares of the medical research company’s stock after selling 295 shares during the quarter. Wrapmanager Inc.’s holdings in Charles River Laboratories International were worth $303,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CRL. abrdn plc grew its stake in shares of Charles River Laboratories International by 872.0% in the fourth quarter. abrdn plc now owns 121,807 shares of the medical research company’s stock valued at $28,795,000 after buying an additional 109,275 shares in the last quarter. Regency Capital Management Inc. DE purchased a new stake in shares of Charles River Laboratories International during the fourth quarter valued at approximately $3,703,000. WCM Investment Management LLC acquired a new position in shares of Charles River Laboratories International during the fourth quarter worth $1,396,000. DekaBank Deutsche Girozentrale boosted its stake in shares of Charles River Laboratories International by 98.6% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 14,094 shares of the medical research company’s stock valued at $3,333,000 after purchasing an additional 6,997 shares during the period. Finally, AMG National Trust Bank acquired a new stake in Charles River Laboratories International during the 3rd quarter valued at $1,119,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analyst Ratings Changes

CRL has been the subject of a number of analyst reports. Guggenheim cut shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Robert W. Baird lifted their price objective on Charles River Laboratories International from $252.00 to $268.00 and gave the stock an “outperform” rating in a report on Thursday, February 15th. Citigroup increased their target price on Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a research note on Thursday, February 15th. TheStreet upgraded shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a research note on Friday, March 1st. Finally, Evercore ISI increased their price objective on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the company an “outperform” rating in a research note on Thursday, February 15th. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Charles River Laboratories International currently has an average rating of “Moderate Buy” and an average target price of $253.23.

Charles River Laboratories International Stock Performance

Shares of NYSE:CRL traded down $5.18 during trading on Thursday, hitting $230.11. 1,004,419 shares of the company traded hands, compared to its average volume of 548,995. The stock has a market capitalization of $11.85 billion, a price-to-earnings ratio of 24.98, a PEG ratio of 1.83 and a beta of 1.44. Charles River Laboratories International, Inc. has a one year low of $161.65 and a one year high of $275.00. The company has a quick ratio of 1.16, a current ratio of 1.52 and a debt-to-equity ratio of 0.73. The business’s fifty day moving average is $250.70 and its 200-day moving average is $225.27.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.39 by $0.07. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $991.25 million. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The firm’s quarterly revenue was down 7.9% compared to the same quarter last year. During the same period last year, the business posted $2.98 earnings per share. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 5,882 shares of the business’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the transaction, the executive vice president now owns 2,596 shares in the company, valued at approximately $626,155.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the transaction, the executive vice president now directly owns 2,596 shares in the company, valued at $626,155.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Victoria L. Creamer sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $253.70, for a total value of $1,268,500.00. Following the sale, the executive vice president now directly owns 13,550 shares in the company, valued at approximately $3,437,635. The disclosure for this sale can be found here. Over the last three months, insiders sold 14,932 shares of company stock worth $3,693,663. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).